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Melioidosis (infection caused by Burkholderia pseudomallei) requires a prolonged course of oral antibiotics
following initial intravenous therapy to reduce the risk of relapse after cessation of treatment. The current
recommendation is a four-drug regimen (trimethoprim [TMP], sulfamethoxazole [SMX], doxycycline, and
chloramphenicol) and a total treatment time of 12 to 20 weeks. Drug side effects are common; the aim of this
study was to compare the efficacy and tolerance of the four-drug regimen with a three-drug regimen (TMP-
SMX and doxycycline). An open-label, randomized trial was conducted in northeast Thailand. A total of 180
adult Thai patients were enrolled, of which 91 were allocated to the four-drug regimen and 89 to the three-drug
regimen. The trial was terminated early due to poor drug tolerance, particularly of the four-drug regimen. The
culture-confirmed relapse rates at 1 year were 6.6% and 5.6% for the four- and three-drug regimens, respec-
tively (P  0.79). The three-drug regimen was better tolerated than the four-drug regimen; 36% of patients
receiving four drugs and 19% of patients receiving three drugs required a switch in therapy due to side effects
(P  0.01). The duration of oral therapy was significantly associated with relapse; after adjustment for
confounders, patients receiving less than 12 weeks of oral therapy had a 5.7-fold increase of relapse or death.
A combination of TMP-SMX and doxycycline is as effective as and better tolerated than the conventional
four-drug regimen for the oral treatment phase of melioidosis.
Melioidosis, the infection caused by Burkholderia pseudomal-
lei, is endemic to southeast Asia and northern Australia. Large
numbers of cases are seen in northeast Thailand, where it
constitutes almost 20% of community-acquired bacteremia (2).
An important feature of disease is that recurrence is common
after completion of antibiotic treatment and apparent cure,
occurring in 3 to 25% of patients. Molecular typing indicates
that most cases of recurrence are due to recrudescence of the
original infecting strain (relapse) (3, 8). Prolonged therapy has
been demonstrated to reduce relapse. Current treatment rec-
ommendations include administration of intravenous antibiot-
ics (ceftazidime or a carbapenem) for at least 10 days, followed
by oral antibiotics for at least 12 weeks.
Our current oral regimen is a four-drug combination of
trimethoprim-sulfamethoxazole (TMP-SMX), doxycycline, and
chloramphenicol. This regimen is associated with high rates of
adverse events, including gastrointestinal intolerance, anemia,
and allergic reactions. In other centers, the use of a three-drug
regimen or even TMP-SMX alone has been associated with
low relapse rates (6, 7). Higher relapse rates have been found
during clinical trials of amoxicillin-clavulanate with supple-
mental amoxicillin, doxycycline monotherapy, and a combina-
tion of azithromycin and ciprofloxacin (5, 6, 11). The aim of
this study was to examine the efficacy and side effects associ-
ated with the four-drug (TMP-SMX, doxycycline, and chlor-
amphenicol) regimen versus the three-drug (TMP-SMX and
doxycycline) regimen.
MATERIALS AND METHODS
An open-label, randomized study was conducted at Sappasithiprasong Hospi-
tal, Ubon Ratchathani, northeast Thailand. The study protocol was approved by
the Ethical Committee of the Ministry of Public Health, Royal Government of
Thailand. Recruitment was undertaken between July 1998 and October 2002
during twice-daily rounds of the medical, surgical, and intensive care wards.
Patients with suspected melioidosis were examined, and microbiological samples
(blood, sputum, throat swab, urine, and pus) were obtained for bacterial culture.
Patients were enrolled into the study if they were 15 years of age or older, had
completed an intravenous course of appropriate antibiotics for culture-con-
firmed melioidosis, had provided written informed consent to participate, and
agreed to outpatient follow-up for at least 20 weeks. Patients with mild disease
who did not require intravenous antibiotics were also eligible. Exclusion criteria
were being pregnant or lactating; known intolerance or allergy to TMP-SMX,
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doxycycline, or chloramphenicol; and infection with a strain of B. pseudomallei
with in vitro resistance to doxycycline or chloramphenicol as determined by disk
diffusion. Diabetes was defined by contemporary definitions (1). Renal impair-
ment was defined as a creatinine level greater than 2.0 mg/dl prior to admission.
Randomization was performed by a computer-generated sequence and was
balanced after each block of 10 patients. Sealed envelopes were prepared by a
member of the research unit who was not involved in enrollment. These were
opened by a member of the study team following a decision to start oral treat-
ment. Patients were randomly allocated to receive TMP-SMX (8 mg TMP and 40
mg SMX/kg of body weight daily; maximum dose, 160 mg TMP and 800 mg SMX
twice daily), doxycycline (4 mg/kg daily; maximum dose, 100 mg twice daily), and
chloramphenicol (40 mg/kg daily; maximum dose, 500 mg four times daily for the
first 4 weeks of oral therapy) or TMP-SMX and doxycycline without chloram-
phenicol at the same doses. All study drugs were manufactured either by Thai
pharmaceutical companies or the Government Pharmaceutical Organization and
were provided free to study patients. Minimum duration of oral treatment was 12
weeks, but total duration was based on clinical history and the course of illness.
Patients that had evidence of deep-seated infection (such as undrained visceral
abscesses or infections involving bones or joints) or those with more severe
disease on presentation tended to receive longer courses of antibiotics. Con-
versely, patients with mild disease, such as infections involving skin and soft
tissue, or patients with parotid abscesses tended to receive shorter courses of
antibiotics. Duration of antibiotic treatment was determined by a single clinician
with extensive experience in the clinical management of melioidosis (W. Cha-
owagul), who undertook outpatient review within 4 weeks after discharge and
periodically thereafter based on clinical progress.
Follow-up was continued until July 2004. Patients were primarily monitored
through the outpatient department. Nonattendees were sent letters inquiring
about their subsequent clinical course and visited at home by the study team if
necessary.
Patients who failed to attend clinic appointments were deemed to have ceased
their medications when last reviewed in the outpatient department. Recurrence
of disease was treated as for the primary episode, with readmission for investi-
gation and intensive intravenous therapy if required, followed by the four-drug
conventional combination. Amoxicillin-clavulanate with supplemental amoxicil-
lin was used for patients who developed suspected drug allergies.
The primary outcome measure was culture-confirmed relapse or time to death
attributable to melioidosis. “Clinical relapse” was also determined; this was
defined as possible relapse characterized by clinical features compatible with
melioidosis that was treated with antibiotics active against B. pseudomallei but
was culture negative. Mortality was categorized as attributable to primary infec-
tion or relapse or attributable to other causes.
Time to outcome was measured as the start of oral treatment to relapse or
attributable death. Censoring events were death from causes other than culture-
confirmed or clinical relapse and loss to follow-up. A comparison of adverse drug
events was made between each group.
The original study design called for 226 patients to achieve an 80% power to
detect a difference in relapse rates of 25% and 10% at the 0.05 significance level.
All analyses were done on an intention-to-treat basis and then repeated per
protocol. In the per-protocol analyses, patients who switched treatment to the
other study arm were reallocated according to the final treatment they received.
In this analysis, patients who changed treatment regimens to antibiotics that did
not include a study regimen were not reallocated.
Statistical tests were performed using the statistical program STATA/SE,
version 8.0 (StataCorp LP, College Station, Tex.). Comparisons of continuous
data were performed using a Student’s t test or the Mann Whitney U test where
appropriate. Proportions were compared using Fisher’s exact test. Time-to-event
endpoints were compared using the log-rank test or Wilcoxon test as appropriate
and were depicted graphically using a Kaplan-Meier graph. A Cox proportional
hazards model was used to adjust the treatment effect for potential confounding
factors; the following variables were considered in the forward-variable selection
procedure: age, distribution of infection, initial use of ceftazidime, history of
chronic renal failure, diabetes mellitus, and failure to complete at least 12 weeks
of therapy for analysis of relapse after cessation of oral treatment. The final Cox
proportional hazards models were reanalyzed with TMP-SMX resistance as a
variable to explore its effect.
Susceptibility to ceftazidime, imipenem, chloramphenicol, doxycycline, and
amoxicillin-clavulanate was performed by the Kirby-Bauer disk diffusion test. As
TMP-SMX susceptibility testing by this method is not reliable and testing for
MICs was not in routine use at this time (10), test results were not reported to
clinicians during this trial. Susceptibility testing using the Etest (AB Biodisk) was
retrospectively performed on isolates stored at 70°C in trypticase soy broth
with 15% glycerol using NCCLS methodology and breakpoints for B. pseudomal-
lei (susceptible, 2/38 g trimethoprim-sulfamethoxazole; resistant, 4/76 g)
(9, 12).
RESULTS
A total of 789 patients presented to Sappasithiprasong Hos-
pital with culture-confirmed melioidosis between July 1998 and
October 2002. The number of patients included at each stage
of the study is illustrated in Fig. 1. The decision was taken to
terminate the trial early after enrollment of 180 patients, since
the level of drug intolerance, particularly to the four-drug
regimen, was very high. A post hoc power calculation sug-
gested that the power to detect a difference in relapse rates of
25% and 10% at the 0.05 significance level was reduced to
69%. Baseline characteristics of the study patients are shown in
Table 1. These were similar, and most of the patients were
treated with ceftazidime as initial intravenous therapy. Two
patients in the three-drug group had mild disease and did not
receive intravenous therapy.
The median duration of follow-up of patients without re-
lapse was 45 weeks, with a total duration of follow-up of 11,691
patient weeks. Similar proportions of patients in both groups
were lost to follow-up before the end of the study. The median
duration of the allocated oral treatment in patients was longer
in the three-drug group (10.1 weeks versus 3.7 weeks; P 
0.046). The total duration of oral treatment including the sub-
sequent regimens after cessation of the allocated regimen was
similar (19 versus 17 weeks; P  0.21) (Table 2).
Relapse was analyzed from the start of therapy to take
account of cases that developed early relapse following an
initial response to treatment. Results of patient outcome are
shown in Table 2. The culture-confirmed relapse rates at 1 year
were 6.6% and 5.6% for the four- and three-drug regimens,
respectively (P  0.79). Case fatality for the three-drug and
four-drug groups was 14% and 11%, respectively; this was
equal when considering mortality attributable to infection
(10.1% versus 9%; P  1.00). A Kaplan-Meier graph for time
to relapse and/or death from melioidosis during follow-up is
shown in Fig. 2. There were no differences between the three-
drug group and the four-drug group at 1 year (P  0.96,
Wilcoxon test), at 1.5 years (P  0.79, Wilcoxon test), or at 2
years (P  0.86, Wilcoxon test), respectively.
In a Cox regression analysis, age was found to be signifi-
cantly associated with the risk of treatment failure (hazard
ratio [HR] 1.05; 95% confidence interval [CI], 1.01 and 1.08;
P  0.01). In the final model, treatment allocation was not
significantly associated with outcome (HR  1.11; 95% CI,
0.50 and 2.47; P  0.80 for the four-drug group compared to
the three-drug group).
The culture-confirmed relapse rate for 124 patients who
received a total of at least 12 weeks of oral therapy was 11.8%
in the four-drug group and 5.4% in the three-drug group (P 
0.296, log-rank test). In a multiple-variable Cox proportional
hazards model, failure to complete at least 12 weeks of therapy
was associated with a shorter time to relapse or death (HR 
5.70; 95% CI, 2.61 and 12.45; P  0.001). Adjusting for these
predictors, the allocated treatment arm was not associated with
outcome (HR  1.28; 95% CI, 0.58 and 2.85; P  0.54).
There were nine protocol violations, as follows. Amoxicillin-
clavulanate with supplemental amoxicillin was substituted for
the allocated treatment in seven patients (two patients allo-











cated to four drugs and five patients to three drugs). Two
patients allocated to receive four-drug therapy received the
three-drug regimen; these were included in the analysis. In a
per-protocol analysis, culture-confirmed relapse was not signif-
icantly different between the two groups (8.1% in the four-drug
group versus 9.8% in the three-drug group; P  0.47, log-rank
test).
A total of 169 B. pseudomallei isolates were available for
susceptibility testing. Of these, 9 out of 82 (11%) in the four-
drug group and 7 out of 87 (8.1%) in the three-drug group
were resistant to TMP-SMX by Etest (P 0.52). In a multiple-
variable Cox proportional hazards model adjusting for allo-
cated regimen, age, and failure to complete 12 weeks of ther-
apy, TMP-SMX resistance was not statistically associated with
shorter relapse-free duration from the commencement of oral
therapy (HR  2.05; 95% CI, 0.44 and 9.62; P  0.36) or the
cessation of oral therapy (HR  1.62; 95% CI, 0.20 and 13.02;
P  0.65).
In total, 63 patients required a change in treatment, of which
48 (53%) were in the four-drug group and 22 (25%) in the
three-drug group (P  0.001) (Table 2). Patients randomized
to receive four drugs switched treatment to amoxicillin-clavu-
lanate (n  23) or three-drug therapy (n  25). Patients ran-
domized to the three-drug therapy switched treatment to
amoxicillin-clavulanate (n  17), TMP-SMX (n  4), or doxy-
cycline (n  1). A higher proportion of patients reported
adverse drug events in the four-drug group (Table 3) and
switched therapy within the first four weeks: 42 out of 48
FIG. 1. Flow chart illustrating patients included at each stage of the study.











(87.5% in the four-drug group) versus 13 out of 22 (59.1% in
the three-drug group; P  0.007). Gastrointestinal intolerance
and anemia were reported at lower rates in the three-drug
group. Allergic phenomena were similar in both groups. In the
four-drug group, chloramphenicol was ceased prior to 4 weeks
in 41 patients (45%).
DISCUSSION
This six-year trial is the largest study of eradication therapy
for melioidosis reported to date. The data presented suggest
that the 4-week chloramphenicol component of the four-drug
regimen is associated with significant intolerance. The inability
TABLE 1. Admission details at randomization
Variable
No. of patients positive
with the four-drug
regimen (n  91)
No. of patients positive
with the three-drug
regimen (n  89)
Significance
Male 53 (58.2%) 58 (65.2%) 0.34
Age (yr) (median, range) 47 (15–70) 47 (16–74) 0.79
Rice farmer 77 (84.6%) 72 (80.9%) 0.51
Diabetes mellitus 40 (44.0%) 35 (39.3%) 0.53
Chronic renal impairment 2 (2.2%) 5 (5.6%) 0.28
Blood culture positive 41 (45.1%) 41 (46.1%) 0.89
Distribution of infectiona 0.87
Disseminated 20 (22.0%) 21 (23.6%)
Septicemic 21 (23.1%) 19 (21.3%)
Multifocal 9 (9.9%) 12 (13.5%)
Localized 41 (45.1%) 37 (41.6%)
First intravenous drug received 0.12
Ceftazidime 86 (94.5%) 81 (91.0%)
Imipenem 1 (1.1%) 2 (2.2%)
Amoxicillin-clavulanate 4 (4.4%) 4 (4.5%)
None 0 2 (2.2%)
Duration of intravenous therapy (days, range) 13 (1–50) 13 (0–56) 0.79
a Disseminated disease was defined as blood culture positive plus 2 organs involved; septicemic, blood culture positive 1 or no organ involved; multifocal, 2
organs involved but blood culture negative; localized, 1 organ involved and blood culture negative.
TABLE 2. Patient outcomes
Variable
No. of patients positive
with the four-drug
regimen (n  91)
No. of patients positive
with the three-drug
regimen (n  89)
P value
Relapse to end of follow-up period
Culture confirmed 9 (9.9%) 7 (7.9%) 0.63
Clinical 9 (9.9%) 7 (7.9%) 0.63
Overall 18 (19.8%) 14 (15.7%) 0.48
Died 10 (11.0%) 12 (13.5%) 0.61
Attributable to primary or relapse infection 9 (9.9%) 9 (10.1%) 0.96
Other cause 0 3a (3.4%) 0.12
Unknown 1 (1.1%) 0 1.00
Switch in treatment 48 (52.7%) 22 (24.7%) 0.001
Due to adverse drug event 33 (36.3%) 17 (19.1%) 0.01
Due to other reasons 15 (16.5%) 5 (5.6%) 0.02
Follow-up of less than 3 months 14 (15.4%) 22 (24.7%) 0.12
Duration of allocated regimen, median (IQR)b 3.7 (1.9–18.1) 10.1 (2.3–19.6) 0.046
12 weeks 43 (47.3%) 47 (52.8%) 0.46
12 to 20 weeks 36 (39.6%) 28 (31.5%) 0.26
20 weeks 12 (13.2%) 14 (15.7%) 0.63
Duration of total oral treatment, median (IQR) 19 (13.3–20.3) 17 (4.0–20.6) 0.17
12 weeks 23 (25.3%) 33 (37.1%) 0.09
12 to 20 weeks 41 (45.1%) 32 (36.0%) 0.21
20 weeks 27 (29.7%) 24 (27.0%) 0.69
a Death due to human immunodeficiency virus coinfection (1), heart disease (1), and non-melioidosis postoperative wound infection (1).
b IQR, interquartile range.











to adhere to this regimen limited our ability to draw conclu-
sions regarding the relative efficacy of four drugs versus three
drugs. Given these limitations, it is not surprising that relapse
rates were similar in both groups.
Other alternatives to the four-drug regimen have been ex-
plored previously. A ciprofloxacin-azithromycin regimen and
doxycycline monotherapy have both been associated with re-
lapse rates exceeding 20% in clinical trials in Thailand (5, 6). In
one of these trials the comparator arm was the three-drug
regimen in which only one relapse was recorded in 33 patients
that received this regimen (relapse rate, 3%; 95% CI, 0 and
16%) (6). Quinolone monotherapy was associated with a re-
lapse rate of 29% in an uncontrolled study (4). Amoxicillin-
clavulanate with supplemental amoxicillin was associated with
a higher relapse rate than the four-drug conventional therapy
in 101 patients, although poor adherence to the 20-week
course of therapy appeared to be a more important factor than
antibiotic regimen (11). Factors previously demonstrated to be
associated with relapse include eradication regimens of less
than 12 weeks, severity of disease, and the use of amoxicillin-
clavulanate in place of the intensive intravenous phase (3).
Higher rates of culture-positive relapse were seen by the end
of this trial compared with previous studies. This may be ex-
plained in part by the longer follow-up (up to 5.5 years) and
larger sample size (two to three times) in this study compared
to those reported previously, our active surveillance for follow-
up, and the poor tolerance to the regimens generally. When
the analysis time was limited to 52 weeks, the overall relapse
rate was similar to that of previous trials (6% compared to 2 to
4%) (5, 6, 11). These findings reinforce the need for ongoing
follow-up as relapse may occur many years after initial infec-
tion (8).
A high rate of TMP-SMX resistance in clinical isolates was
demonstrated in this study. Testing for TMP-SMX has been
FIG. 2. Kaplan-Meier plot analysis illustrating time to death or culture-confirmed relapse after start of oral therapy for the four-drug versus
three-drug groups. Numbers in brackets represent the number of patients at risk at 0.5, 1, 1.5, 2, and 3 years from left to right, respectively (the
upper row shows the three-drug group and the lower row shows the four-drug group).









Nausea, vomiting, or abdominal pain 14 (15.4%) 6 (6.7%) 0.07
Rash or other allergic reaction 9 (9.9%) 8 (9.0%) 0.84
Photosensitivity 6 (6.6%) 3 (3.4%) 0.50
Anemia 7 (7.7%) 1 (1.1%) 0.06
Angular stomatitis 3 (3.3%) 0 0.25
Anorexia 3 (3.3%) 0 0.25
Chest discomfort 1 (1.1%) 0 1.00
Dry mouth 1 (1.1%) 0 1.00
Seizure 1 (1.1%) 0 1.00
Azotemia 0 1 (1.1%) 0.49
Other complications 4 (4.4%) 3 (3.4%) 1.00
Any adverse event 37 (40.7%) 20 (22.5%) 0.009











problematic; testing by the Kirby Bauer disk diffusion tech-
nique has tended to overestimate the rates of resistance (10).
We have recently reported the results of TMP-SMX suscepti-
bility testing by Etest for a large number of isolates stored at
our center, including those from patients in this study (12). The
high rate of resistance to TMP-SMX has clear implications for
a potential future trial of TMP-SMX alone in this region. No
major differences were seen in patients infected with TMP-
SMX-resistant isolates, but this study was underpowered to
examine the effect of resistance on relapse rates reflected in
the wide confidence intervals in the estimate.
There are several limitations to this open-label trial. Aware-
ness of the treatment received may have influenced reporting
of adverse events, although it is unlikely to have influenced the
more objective endpoint of culture-confirmed relapse. A sig-
nificant proportion of patients were lost to follow-up, high-
lighting the difficulty in monitoring long-term outcome in this
primarily rural population. The high rate of switching of drug
regimens reflects the poor tolerance of both regimens. Adher-
ence to therapy was not formally assessed by pill counts or drug
levels.
This study suggests that the three-drug regimen is better
tolerated and is as effective as the four-drug regimen for oral
eradication therapy of melioidosis in adults. However, both
regimens in this study were associated with significant rates of
intolerance. As tolerance is a key factor in promoting adher-
ence to prolonged antibiotic therapy, it is likely that the use of
simpler therapies are likely to improve outcomes. TMP-SMX
alone is used for eradication therapy in Australia (7); a pro-
spective, multicenter randomized trial is now planned to com-
pare the efficacy and side effect profile of the three-drug reg-
imen versus TMP-SMX alone.
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